📅 Less than 60 days until meaningful change in patient access. Beginning January 1, 2026, Category I CPT code assigned to Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures will take effect. This update enhances clarity for providers delivering PENFS

Join NeurAxis at the NASPGHAN Annual Meeting, November 5 - 8 in Chicago, IL (Booth #314). Meet our team: Brian Carrico, Ryan Kuhlman, Doug Terry, Matt Carrico, and Trisha Baumgardt. Stop by to discuss IB-Stim®, a non-drug, outpatient therapy FDA-cleared for children &

We’re proud to announce and celebrate Levine Children’s Hospital – Charlotte, NC designation as an IB-Stim® Center of Excellence. 🎉 Through clinical expertise and dedication to pediatric care, the team at Levine Children’s has demonstrated leadership in advancing treatment for

More than medication, IB-Stim® supports a neurophysiologic approach to pediatric abdominal pain. FDA-cleared for patients ages 8 to 21 with functional abdominal pain associated with IBS and FD, IB-Stim is a wearable neuromodulation option that fits into standard care. Learn

Too often, patients with chronic constipation are treated for symptoms while the underlying dysfunction remains untested. RED™ offers a quick, qualitative way to assess expulsion ability and screen for rectal hypersensitivity. All without disrupting clinical flow. Learn more:

On January 1, 2026, a Category I CPT code will go into effect for reporting Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures. IB-Stim® is checking all the boxes! Category I CPT codes are assigned by the AMA for reporting services that are: ✅Well-established

What if you could give pediatric patients a solution for functional abdominal pain without the side effects of commonly prescribed medications? IB-Stim is an FDA-cleared, drug-free treatment for patients ages 8 to 21 with functional abdominal pain in IBS and functional

Heading to ANMS 2025? So are we! Stop by and say hello! The NeurAxis team will be exhibiting at the American Neurogastroenterology and Motility Society Annual Meeting from August 8–10 in Minneapolis. Stop by our booth and say hello to Matt Carrico and Doug Terry. We will be at

IB-Stim gives pediatric and adolescent patients ages 8 to 21 and providers an option for managing abdominal pain associated with IBS and Functional Dyspepsia. Backed by clinical evidence and FDA clearance, it supports brain-gut modulation in outpatient care settings. How it

Some patients with constipation don’t respond to traditional therapies because the cause is not colonic transit, but pelvic floor dysfunction. RED helps identify expulsion difficulties or rectal hypersensitivity right in your office.* Learn how RED supports targeted care:

In a randomized controlled trial, 81% of patients using IB-Stim reported clinically meaningful symptom improvement vs 26% with sham using the Symptom Response Scale (SRS). A score of +2 or more on the SRS was used to define global symptom improvement.* Explore the full data:

For many GI providers, lack of access to specialized motility equipment limits the ability to assess chronic constipation. RED offers a practical, in-office solution to evaluate rectal expulsion and identify rectal hypersensitivity without electronics, software, or a capital

IB-Stim is FDA-cleared for children and adolescents ages 8 to 21 with abdominal pain associated with IBS and functional dyspepsia. This non-drug, outpatient therapy uses percutaneous electrical nerve field stimulation (PENFS) to modulate the brain-gut axis via small electrodes

RED™ (Rectal Expulsion Device) uses proprietary foam technology that mimics stool, no air or water needed. This office-based test capable of offering real-time insights into pelvic floor dysfunction and rectal hypersensitivity without disrupting routine workflow. 🔹 Capable of

Trust matters in clinical decision-making. In a post-use survey, 95% of respondents indicated they would recommend IB-Stim to a friend or family member.* IB-Stim is FDA-cleared for children and adolescents ages 8 to 21 with abdominal pain associated with irritable bowel syndrome

Only 2% of patients with constipation are referred for anorectal testing.* That means 98% of patients experiencing constipation don’t receive anorectal testing.* Our mission is simple: Empower every Gastroenterologist to confidently assess pelvic floor dysfunction and rectal

How do you measure the impact of symptom control in a child with chronic pain? For one family, the difference was everything. “This device is life changing. Liam had his longest span of manageable to no pain for almost three months. I got to watch Liam riding his bike to his

Did you know? Up to one-third of patients with chronic constipation experience rectal hypersensitivity.* RED can detect this with a self-inflating balloon that mimics stool at a standardized volume (~52 mL). By delivering clear, actionable results that can inform next steps,

Our mission is to give hope to every patient with chronic constipation. We want every Gastroenterologist practice to be able to safely and confidently perform meaningful anorectal testing without it impacting clinical workflow or requiring a large capital expense. RED is an

NeurAxis was honored to connect with so many providers at DDW Digestive Disease Week® in San Diego! From left to right: Brian Carrico, Haley Weaver, Dr. Adrian Miranda, and Matt Kelker. Thank you to all who stopped by to discuss RED, IB-Stim, and advancing GI care. For